<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

In April of this year, Dr. Jacob Langston, chief resident PGY-5 in the department of radiation oncology at the University of Colorado Anschutz Medical Campus Aurora, and his colleagues published results from a study in the journal Lung Cancer, in which 12 patients with non-small cell lung cancer (NSCLC) were treated with tyrosine kinase inhibitors first before they proceeded to stereotactic radiotherapy.